Eurofins Scientific

A decent end to FY24: investors jittery with biopharma headwinds

31/01/25 -"During FY24, Eurofins’ revenue was in line with market expectations, but the EPS and FCF outperformed. The initial knee-jerk reaction was attributable to continued weakness in the Biopharma ..."

PDF page sample
Pages
59
Language
English
Published on
31/01/25
Download
You may also be interested by these reports :
09/05/25
Adecco delivered a solid Q1 2025, with the Adecco GBU showing resilience, supported by growth in the Americas and Asia Pacific. The FESCO joint ...
08/05/25
Organic sales growth and operating margin improvement were in line with expectations, with all divisions contributing to the overall performance. At ...
30/04/25
Rentokil’s (Buy; UK) share price has declined by 11% since we last teased about it in May 2024.  Things started out well when the activist investor ...
25/04/25
BV’s Q1 sales figures were marginally ahead of the consensus in absolute terms, but exceeded expectations on organic growth. Sales growth was ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO